Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer

다국어 초록 (Multilingual Abstract)

Epidermal growth factor receptor (EGFR) overexpression is common in head and neck squamous cell carcinoma.
Targeted therapy specifically directed towards EGFR has been an area of keen interest in head and neck cancer research, as EGFR is potentially an integration point for convergent signaling. Despite the latest advancements in cancer diagnostics and therapeutics against EGFR, the survival rates of patients with advanced head and neck cancer remain disappointing due to anti-EGFR resistance. This review article will discuss recent multilateral efforts to discover and validate actionable strategies that involve signaling pathways in heterogenous head and neck cancer and to overcome anti-EGFR resistance in the era of precision medicine. Particularly, this review will discuss in detail the issue of cancer metabolism, which has recently emerged as a novel mechanism by which head and neck cancer may be successfully controlled according to different perspectives.

참고문헌 (Reference)

1 Matoba, S., "p53 regulates mitochondrial respiration" 312 : 1650-1653, 2006

2 Singh, B., "p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas" 16 : 984-993, 2002

3 Jiang, P., "p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase" 13 : 310-316, 2011

4 Huang, S., "p53 modulates acquired resistance to EGFR inhibitors and radiation" 71 : 7071-7079, 2011

5 Stabile, L. P., "c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met" 19 : 380-392, 2013

6 Brosh, R., "When mutants gain new powers : news from the mutant p53 field" 9 : 701-713, 2009

7 Bianco, R., "Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells" 14 : 5069-5080, 2008

8 Vander Heiden, M. G., "Understanding the Warburg effect : the metabolic requirements of cell proliferation" 324 : 1029-1033, 2009

9 Wheeler, D. L., "Understanding resistance to EGFR inhibitors-impact on future treatment strategies" 7 : 493-507, 2010

10 Valastyan, S., "Tumor metastasis : molecular insights and evolving paradigms" 147 : 275-292, 2011

11 Wang, S., "Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer" 9 : 34-, 2016

12 Cammaroto, G., "The role of PET/CT in the management of patients affected by head and neck tumors : a review of the literature" 273 : 1961-1973, 2016

13 Feng, Z., "The regulation of AMPK beta1, TSC2, and PTEN expression by p53 : stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways" 67 : 3043-3053, 2007

14 Brand, T. M., "The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor" 10 : eaag1064-, 2017

15 Chong, C. R., "The quest to overcome resistance to EGFRtargeted therapies in cancer" 19 : 1389-1400, 2013

16 Stransky, N., "The mutational landscape of head and neck squamous cell carcinoma" 333 : 1157-1160, 2011

17 Röhrig, F., "The multifaceted roles of fatty acid synthesis in cancer" 16 : 732-749, 2016

18 Leemans, C. R., "The molecular biology of head and neck cancer" 11 : 9-22, 2011

19 DeBerardinis, R. J., "The biology of cancer : metabolic reprogramming fuels cell growth and proliferation" 7 : 11-20, 2008

20 Seiwert, T. Y., "The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma" 69 : 3021-3031, 2009

21 Pascual, G., "Targeting metastasis-initiating cells through the fatty acid receptor CD36" 541 : 41-45, 2017

22 Yamamoto, M., "Targeting metabolic pathways for head and neck cancers therapeutics" 36 : 503-514, 2017

23 Cathcart, J., "Targeting matrix metalloproteinases in cancer : bringing new life to old ideas" 2 : 26-34, 2015

24 von Roemeling, C. A., "Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma" 20 : 159-166, 2016

25 Ben Sahra, I., "Targeting cancer cell metabolism : the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells" 70 : 2465-2475, 2010

26 Zhang, J., "Targeting HER(ERBB)signaling in head and neck cancer : an essential update" 45 : 74-86, 2015

27 Zhou, B. B., "Targeting ADAM-mediated ligand cleavage to inhibit HER3and EGFR pathways in non-small cell lung cancer" 10 : 39-50, 2006

28 Furuuchi, K., "Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors" 178 : 1021-1029, 2007

29 Bensaad, K., "TIGAR, a p53-inducible regulator of glycolysis and apoptosis" 126 : 107-120, 2006

30 Weihua, Z., "Survival of cancer cells is maintained by EGFR independent of its kinase activity" 13 : 385-393, 2008

31 Weinhouse, S., "Studies on the fate of isotopically labeled metabolites in the oxidative metabolism of tumors" 11 : 585-591, 1951

32 Pepino, M. Y., "Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism" 34 : 281-303, 2014

33 Alam, N., "Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung" 11 : E1-E4, 2010

34 Erjala, K., "Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor(EGFR)amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells" 12 : 4103-4111, 2006

35 Yu, H. A., "Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers" 11 : 161-169, 2013

36 Zhang, Q., "SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells" 64 : 6166-6173, 2004

37 Wang, S. J., "Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance" 178 : 956-963, 2011

38 Fouad, Y. A., "Revisiting the hallmarks of cancer" 7 : 1016-1036, 2017

39 She, Q. B., "Resistance to gefitinib in PTENnull HER overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling" 9 : 4340-4346, 2003

40 Hay, N., "Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?" 16 : 635-649, 2016

41 Torre, C., "Reduction of hyaluronanCD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling" 136 : 493-501, 2010

42 Harrington, K., "Randomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck : rationale for future randomised trials in human papilloma virus-negative disease" 49 : 1609-1618, 2013

43 Kim, H. S., "Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck" 21 : 544-552, 2015

44 Wirth, L. J., "Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck" 21 : 342-347, 2010

45 Weinhouse, S., "Oxidative metabolism of neoplastic tissues" 3 : 269-325, 1955

46 Iida, M., "Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy" 13 : 242-, 2014

47 Jia, Y., "Overcoming EGFR(T790M)and EGFR(C797S)resistance with mutant-selective allosteric inhibitors" 534 : 129-132, 2016

48 Li, C., "Nuclear EGFR contributes to acquired resistance to cetuximab" 28 : 3801-3813, 2009

49 Remacle, A. G., "Novel MT1-MMP small molecule inhibitors based on insights into hemopexin domain function in tumor growth" 72 : 2339-2349, 2012

50 Mori, H., "New insight into the role of MMP14 in metabolic balance" 4 : e2142-, 2016

51 Wilson, T. R., "Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers" 20 : 158-172, 2011

52 Sauer, L., "Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells" 29 : 2628-2637, 2010

53 Sok, J. C., "Mutant epidermal growth factor receptor(EGFRvIII)contributes to head and neck cancer growth and resistance to EGFR targeting" 12 : 5064-5073, 2006

54 Min, K. W., "Moonlighting proteins in cancer" 370 : 108-116, 2016

55 Pahwa, S., "Monitoring and inhibiting MT1-MMP during cancer initiation and progression" 6 : 416-435, 2014

56 Harari, P. M., "Molecular target approaches in head and neck cancer : epidermal growth factor receptor and beyond" 19 : 63-68, 2009

57 Vyas, S., "Mitochondria and cancer" 166 : 555-566, 2016

58 Itoh, Y., "Membrane-type matrix metalloproteinases : Their functions and regulations" 44 : 207-223, 2015

59 Wheeler, D. L., "Mechanisms of acquired resistance to cetuximab : role of HER(ErbB)family members" 27 : 3944-3956, 2008

60 Shiomi, T., "Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases" 60 : 477-496, 2010

61 Rodríguez, D., "Matrix metalloproteinases : What do they not do? New substrates and biological roles identified by murine models and proteomics" 1803 : 39-54, 2010

62 Poincloux, R., "Matrix invasion by tumour cells : a focus on MT1-MMP trafficking to invadopodia" 122 : 3015-3024, 2009

63 Nevo, J., "Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance" 15 : 6570-6581, 2009

64 Basile, J. R., "MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D" 282 : 6899-6905, 2007

65 Muvva, C., "MMpI : a wide range of available compounds of matrix metalloproteinase inhibitors" 11 : e0159321-, 2016

66 Engelman, J. A., "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling" 316 : 1039-1043, 2007

67 Bianco, R., "Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors" 22 : 2812-2822, 2003

68 Clayton, A. H., "Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor : a multidimensional microscopy analysis" 280 : 30392-30399, 2005

69 Pao, W., "KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib" 2 : e17-, 2005

70 Lièvre, A., "KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer" 6 : 3992-3995, 2006

71 Chakravarti, A., "Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling" 62 : 200-207, 2002

72 Wang, S. J., "Hyaluronan-CD44 promotes phospholipase C-mediated Ca2+ signaling and cisplatin resistance in head and neck cancer" 132 : 19-24, 2006

73 Wang, S. J., "Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer" 132 : 771-778, 2006

74 Shames, D. S., "High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck" 8 : e56765-, 2013

75 Yano, S., "Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations" 68 : 9479-9487, 2008

76 Hanahan, D., "Hallmarks of cancer : the next generation" 144 : 646-674, 2011

77 Hartmann, S., "HGF/Met signaling in head and neck cancer : impact on the tumor microenvironment" 22 : 4005-4013, 2016

78 Knowles, L. M., "HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer" 15 : 3740-3750, 2009

79 Wang, D., "HER3 targeting sensitizes HNSCC to cetuximab by reducing HER3 activity and HER2/HER3 dimerization : evidence from cell line and patient-derived xenograft models" 23 : 677-686, 2017

80 Gibbons, D. L., "HER 1-2 punch : dual EGFR targeting deals resistance a deadly blow" 4 : 991-994, 2014

81 Hu, W., "Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function" 107 : 7455-7460, 2010

82 Menendez, J. A., "Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis" 7 : 763-777, 2007

83 Agrawal, N., "Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1" 333 : 1154-1157, 2011

84 Ferlay, J., "Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008" 127 : 2893-2917, 2010

85 Fuchs, B. C., "Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells" 68 : 2391-2399, 2008

86 Holz, C., "Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells" 101 : 158-164, 2011

87 Lu, Y., "Epidermal growth factor receptor(EGFR)ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab" 67 : 8240-8247, 2007

88 Ji, H., "Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors" 103 : 7817-7822, 2006

89 Jimeno, A., "Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents" 65 : 3003-3010, 2005

90 Wheeler, D. L., "Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab" 8 : 696-703, 2009

91 Kalyankrishna, S., "Epidermal growth factor receptor biology in head and neck cancer" 24 : 2666-2672, 2006

92 Kang, H., "Emerging biomarkers in head and neck cancer in the era of genomics" 12 : 11-26, 2015

93 Grandis, J. R., "Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer" 53 : 3579-3584, 1993

94 Kobayashi, S., "EGFR mutation and resistance of non-small-cell lung cancer to gefitinib" 352 : 786-792, 2005

95 Dittmann, K., "EGFR cooperates with glucose transporter SGLT1 to enable chromatin remodeling in response to ionizing radiation" 107 : 247-251, 2013

96 Harris, R. C., "EGF receptor ligands" 284 : 2-13, 2003

97 Wang, S., "EAI045 : the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance" 385 : 51-54, 2017

98 Huang, S., "Dualagent molecular targeting of the epidermal growth factor receptor(EGFR) : combining anti-EGFR antibody with tyrosine kinase inhibitor" 64 : 5355-5362, 2004

99 Huang, S., "Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation" 73 : 824-833, 2013

100 Cheong, J. H., "Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models" 10 : 2350-2362, 2011

101 Janjigian, Y. Y., "Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations" 4 : 1036-1045, 2014

102 Xu, H., "Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells" 17 : 4425-4438, 2011

103 Sen, B., "Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer" 17 : 514-524, 2011

104 Rysman, E., "De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation" 70 : 8117-8126, 2010

105 Li, C., "Dasatinib blocks cetuximab-and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma" 97 : 330-337, 2010

106 Ather, F., "Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab" 8 : e56112-, 2013

107 Elicin, O., "Current role of dacomitinib in head and neck cancer" 25 : 735-742, 2016

108 Wheeler, J. J., "Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer(including squamous cell carcinomas)and wild-type EGFR or resistant mutations" 12 : 2167-2175, 2013

109 Suzuki, S., "Combined inhibition of EMMPRIN and epidermal growth factor receptor prevents the growth and migration of head and neck squamous cell carcinoma cells" 44 : 912-917, 2014

110 Matar, P., "Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib(ZD1839)and the monoclonal antibody cetuximab(IMC-C225) : superiority over single-agent receptor targeting" 10 : 6487-6501, 2004

111 Ribeiro Gomes, J., "Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors" 8 : 1137-1142, 2015

112 Vermorken, J. B., "Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck(SPECTRUM) : an open-label phase 3 randomised trial" 14 : 697-710, 2013

113 Barriere, G., "Circulating tumor cells and epithelial, mesenchymal and stemness markers : characterization of cell subpopulations" 2 : 109-, 2014

114 Carracedo, A., "Cancer metabolism : fatty acid oxidation in the limelight" 13 : 227-232, 2013

115 Hsu, P. P., "Cancer cell metabolism : Warburg and beyond" 134 : 703-707, 2008

116 Wang, S. J., "CD44 variant isoforms in head and neck squamous cell carcinoma progression" 119 : 1518-1530, 2009

117 Ciardiello, F., "Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy" 10 : 784-793, 2004

118 Rêgo, D. F., "Anti-tumor effects of metformin on head and neck carcinoma cell lines : a systematic review" 13 : 554-566, 2017

119 Yu, H. A., "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers" 19 : 2240-2247, 2013

120 Jingtao Luo, "An indispensable role of CPT-1a to survive cancer cells during energy stress through rewiring cancer metabolism" Springer Science and Business Media LLC 37 (37): 15795-15804, 2016

121 Pirazzoli, V., "Afatinib plus cetuximab delays resistance compared to single-agent erlotinib or afatinib in mouse models of TKI-Naïve EGFR L858R-induced lung adenocarcinoma" 22 : 426-435, 2016

122 Madoz-Gurpide, J., "Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer" 13 : 282-, 2015

123 Viloria-Petit, A., "Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo : a role for altered tumor angiogenesis" 61 : 5090-5101, 2001

124 Guix, M., "Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins" 118 : 2609-2619, 2008

125 Pao, W., "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain" 2 : e73-, 2005

126 Thress, K. S., "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M" 21 : 560-562, 2015

127 Brand, T. M., "AXL mediates resistance to cetuximab therapy" 74 : 5152-5164, 2014

128 Giles, K. M., "AXL mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib" 12 : 2541-2558, 2013

129 Brand, T. M., "AXL is a logical molecular target in head and neck squamous cell carcinoma" 21 : 2601-2612, 2015

130 Li, X., "AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab" 6 : 11507-11518, 2015

131 Jeon, S. M., "AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress" 485 : 661-665, 2012

132 Seiwert, T. Y., "A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck" 25 : 1813-1820, 2014

133 Raez, L. E., "A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors" 71 : 523-530, 2016

134 Zhang, D., "2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy" 355 : 176-183, 2014